Concepedia

Identification and characterization of <i>in silico</i>, <i>in vivo</i>, <i>in vitro</i>, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and <i>in silico</i> toxicity studies of its metabolites

Nasser S. Al‐Shakliah, Mohamed W. Attwa, Adnan A. Kadi, Haitham AlRabiah

RSC Advances · 2020 · 34 citations · 33 references

DOIFull text

Open access

Concepts

Abstract

An <italic>in silico</italic> web designer tool was utilized to guide laboratory work for infigratinib metabolism. Sixteen metabolites of infigratinib and seven reactive intermediates (three iminium ions and four 1,4 benzoquinones) were characterized using LC-ITMS.

References

33

Dose translation from animal to human studies revisited

Shannon Reagan‐Shaw, Minakshi Nihal, Nihal Ahmad · The FASEB Journal · 2007 · 6.3K citations

, , +13

The price of innovation: new estimates of drug development costs

Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski · Journal of Health Economics · 2003 · 4.3K citations · Full text

, , +14

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Milind Javle, Maeve A. Lowery, Rachna T. Shroff et al. · Journal of Clinical Oncology · 2017 · 715 citations

, , +15

The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies

Joseph M. Unger, Elise D. Cook, Eric Tai et al. · American Society of Clinical Oncology Educational Book · 2016 · 614 citations

, , +14

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 489 citations · Full text

, , +14